121 related articles for article (PubMed ID: 36029511)
21. Investigating the effect of Integrated Educational Program on the Quality of Life among Cancer Patients: A Clinical Trial Study.
Bayati M; Molavynejad S; Taheri N; Cheraghian B
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3457-3463. PubMed ID: 31759372
[TBL] [Abstract][Full Text] [Related]
22. MMP3 in Comparison to CA 125, HE4 and the ROMA Algorithm in Differentiation of Ovarian Tumors.
Cymbaluk-Ploska A; Chudecka-Glaz A; Surowiec A; Pius-Sadowska E; Machalinski B; Menkiszak J
Asian Pac J Cancer Prev; 2016; 17(5):2597-603. PubMed ID: 27268637
[TBL] [Abstract][Full Text] [Related]
23. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases.
Molina R; Escudero JM; Augé JM; Filella X; Foj L; Torné A; Lejarcegui J; Pahisa J
Tumour Biol; 2011 Dec; 32(6):1087-95. PubMed ID: 21863264
[TBL] [Abstract][Full Text] [Related]
24. [Correlation between eIF3a and HE4 expression and ovarian cancer].
Wang J; Luo C; Wang Y; Tang Y; Fang K; Zeng L; Zhang Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Dec; 39(12):1240-5. PubMed ID: 25544161
[TBL] [Abstract][Full Text] [Related]
25. Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer.
Lee S; Choi S; Lee Y; Chung D; Hong S; Park N
J Obstet Gynaecol Res; 2017 Jan; 43(1):220-227. PubMed ID: 27862665
[TBL] [Abstract][Full Text] [Related]
26. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review.
Dochez V; Caillon H; Vaucel E; Dimet J; Winer N; Ducarme G
J Ovarian Res; 2019 Mar; 12(1):28. PubMed ID: 30917847
[TBL] [Abstract][Full Text] [Related]
27. Quality of life in ovarian cancer patients choosing to receive salvage chemotherapy or palliative treatment.
Srisuttayasathien M; Khemapech N
Asian Pac J Cancer Prev; 2013; 14(12):7669-74. PubMed ID: 24460351
[TBL] [Abstract][Full Text] [Related]
28. The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients.
Steffensen KD; Waldstrøm M; Brandslund I; Petzold M; Jakobsen A
Int J Gynecol Cancer; 2012 Nov; 22(9):1474-82. PubMed ID: 23095772
[TBL] [Abstract][Full Text] [Related]
29. [HE4--a new tumor marker for ovarian cancer].
Manolov V; Marinov B; Vasilev V; Andreeva A
Akush Ginekol (Sofiia); 2011; 50 Suppl 2():11-5. PubMed ID: 22524132
[TBL] [Abstract][Full Text] [Related]
30. The role of HE4 in ovarian cancer: inhibiting tumour cell proliferation and metastasis.
Gao L; Cheng HY; Dong L; Ye X; Liu YN; Chang XH; Cheng YX; Chen J; Ma RQ; Cui H
J Int Med Res; 2011; 39(5):1645-60. PubMed ID: 22117965
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
Dewan R; Dewan A; Jindal M; Bhardawaj M
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
[TBL] [Abstract][Full Text] [Related]
32. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
[TBL] [Abstract][Full Text] [Related]
33. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer.
Kim B; Park Y; Kim B; Ahn HJ; Lee KA; Chung JE; Han SW
J Clin Lab Anal; 2019 Jan; 33(1):e22624. PubMed ID: 30009497
[TBL] [Abstract][Full Text] [Related]
35. The effect of a supportive educational program based on COPE model on caring burden and quality of life in family caregivers of women with breast cancer.
Bahrami M; Farzi S
Iran J Nurs Midwifery Res; 2014 Mar; 19(2):119-26. PubMed ID: 24834079
[TBL] [Abstract][Full Text] [Related]
36. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells.
Wang H; Zhu L; Gao J; Hu Z; Lin B
Oncol Rep; 2015 Jan; 33(1):403-12. PubMed ID: 25354091
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer.
Paek J; Lee SH; Yim GW; Lee M; Kim YJ; Nam EJ; Kim SW; Kim YT
Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):338-42. PubMed ID: 21683503
[TBL] [Abstract][Full Text] [Related]
39. The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: a systematic review and meta-analysis.
Olsen M; Lof P; Stiekema A; van den Broek D; Wilthagen EA; Bossuyt PM; Lok CAR
Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1788-1799. PubMed ID: 34212386
[TBL] [Abstract][Full Text] [Related]
40. Ovarian cancer and normal fallopian tube high WFDC2 expression does not correlate with HE4 serum level.
Gąsiorowska E; Walkowiak GP; Warchoł W; Lemańska A; Jankowska A; Nowak-Markwitz E
Ginekol Pol; 2015 May; 86(5):335-9. PubMed ID: 26117969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
